On January 26, 2016, a motion for authority to use cash management systems was filed in the bankruptcy case of Nuo Therapeutics, Inc. (f/k/a Cytomedix, Inc.) and its affiliates.
The filing was assigned docket number 4 and is described on the court’s official docket as follows:
Motion to Maintain Bank Accounts // Motion for Interim and Final Orders Pursuant to Sections 105(a), 345(b), 363(c)(1), 364, 503, and 507 of the Bankruptcy Code (I) Authorizing Continued Maintenance of Existing Bank Accounts; (II) Authorizing Continued Use of Existing Cash Management System; (III) Authorizing Continued Use of Existing Checks and Business Forms; (IV) Authorizing the Opening and Closing of Bank Accounts; and (V) Waiving the Requirements of Section 345(b) of the Bankruptcy Code Filed By Nuo Therapeutics, Inc. (Skomorucha Owens, Karen) (Entered: 01/26/2016)
Nuo Therapeutics, Inc. (f/k/a Cytomedix, Inc.) filed for bankruptcy protection, or had an involuntary bankruptcy petition filed against it, on January 26, 2016. The bankruptcy case is pending before the United States Bankruptcy Court for the District of Delaware. The case number for the lead bankruptcy case is 16-10192. The bankruptcy case is currently assigned to United States Bankruptcy Judge Mary Walrath. The law firm of Dentons US LLP is acting as lead bankruptcy counsel to Nuo Therapeutics, Inc. (f/k/a Cytomedix, Inc.) in the bankruptcy case.